Xuexin Bai

Xuexin Bai

Auto-generated profile, based on publicly available information

Xuexin Bai

Department of Tuberculosis Control and Prevention, Hangzhou Center for Disease Control and Prevention (Hangzhou Health Supervision Institution), Mingshi 568#, Shangcheng District, Hangzhou, 310021, Zhejiang, China, +86-571-85155039, +86-571-85177371

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2025 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
QCQinglin Cheng
Qinglin Cheng
PCPing Chen
Ping Chen
RDRuoqi Dai
Ruoqi Dai
QJQingjun Jia
Qingjun Jia
XBXuexin Bai
Xuexin Bai
YHYinyan Huang
Yinyan Huang
Background: Tuberculosis (TB) treatment remains a critical global health challenge, as traditional standard of care (SoC) approaches face limitations in accessibility and efficacy. While digital health technologies (DHTs) offer promising solutions to address these gaps, limited evidence exists on their comparative effectiveness. Objective: This study systematically evaluates and compares the impact of diverse DHTs on improving TB treatment outcomes and adherence, aiming to identify optimal strategies across different patient populations. Methods: A systematic search was conducted across PubMed, Cochrane Library, Embase, and Web of Science from database inception through February 28, 2025, with no language restrictions. Eligible studies included randomized controlled trials comparing DHTs with SoC for TB treatment. The primary outcome was treatment success, defined as completion or cure. A random-effects network meta-analysis was performed, calculating odds ratios (OR) and 95% credibility intervals (CrI) to assess treatment effects. Surface under the cumulative ranking curve (SUCRA) values were used to rank intervention effectiveness. This study is registered with PROSPERO (International Prospective Register of Systematic Reviews; CRD42025601199). Results: From 2420 screened studies, 27 randomized controlled trials involving 23,283 patients and eight DHT interventions were included. The network meta-analysis revealed that digital health platforms showed marginal improvements in treatment success (OR=3.44; 95% CrI 0.95-11.67; SUCRA=0.913; P =.05). Compared with SoC, video directly observed treatment (VDOT) significantly improved treatment success (OR=2.39; 95% CrI 1.18-4.75; SUCRA=0.848; P =.01). Medication event reminder monitors significantly enhanced treatment adherence (OR=3.13; 95% CrI 1.55-7.05; SUCRA=0.891; P =.003). Conclusions: Results underscore the significant potential of DHTs to improve TB treatment management. VDOT emerged as the most effective intervention for enhancing treatment success, while medication event reminder monitors demonstrated efficacy in sustaining adherence. Digital health platforms showed promise but require additional validation. Caution is warranted due to potential heterogeneity across studies, which may affect generalizability. This research offers actionable insights for stakeholders aiming to optimize TB management through strategic DHT integration.

1 December 1996 in Environmental Health Perspectives
Verified
Journal Article
Open access
JCJin Cao
Jin Cao
XBXuexin Bai
Xuexin Bai
YZYan Zhao
Yan Zhao
JLJianwei Liu
Jianwei Liu
DZDingyou Zhou
Dingyou Zhou
JWJinsheng Wu
Jinsheng Wu

9 April 2026 in JMIR Medical Informatics
Verified
Journal Article
Open access
QCQinglin Cheng
Qinglin Cheng
QCQiancheng Cao
Qiancheng Cao
WTWeilin Teng
Weilin Teng
RDRuoqi Dai
Ruoqi Dai
QJQingjun Jia
Qingjun Jia
YHYinyan Huang
Yinyan Huang
Background: Pulmonary dysfunctions are common and frequently co-occur with depressive symptoms, worsening outcomes, and increasing health care burden. Clinically usable models for identifying pulmonary dysfunction–depression comorbidity remain limited by suboptimal interpretability, inconsistent validation, and uncertain generalizability. Objective: This study developed and compared logistic regression (LR), Bayesian network (BN), and Extreme Gradient Boosting (XGBoost) models for identifying factors associated with pulmonary dysfunction–depression comorbidity and evaluated their clinical usefulness across different decision thresholds. Methods: Data were drawn from the 2011 and 2015 waves of the China Health and Retirement Longitudinal Study. The analytical sample comprised 1146 adults with confirmed pulmonary dysfunction, of whom 514 (44.9%) exhibited clinically significant depressive symptoms (10-item Center for Epidemiologic Studies Depression Scale [CESD-10] score of ≥10). Models incorporated demographic, biomarker, comorbidity, and behavioral variables. Performance was assessed via discrimination (area under the receiver operating characteristic curve [AUROC]), calibration (Hosmer-Lemeshow test), and decision curve analysis. Sensitivity analyses excluding psychiatric history addressed potential conceptual overlap with the outcome. Results: LR and BN showed similar discrimination across cohorts (AUROC≈0.73), exceeding XGBoost (0.690 training; 0.650 validation). LR had the most balanced validation performance (specificity 0.721; sensitivity 0.647), whereas BN favored sensitivity (0.884) over specificity (0.401). Training calibration was good for LR or BN, but only LR remained acceptable in validation; XGBoost was miscalibrated. XGBoost’s training net benefit did not generalize. Psychiatric history was the strongest factor (odds ratio 3.46‐7.63), followed by nephropathy, arthritis, and gastropathy; BMI and household registration were inversely associated. Excluding psychiatric history modestly reduced AUROC. With 20 shared predictors, AUROCs converged (0.658‐0.665), BN calibrated best, LR or BN remained sensitivity-forward, and XGBoost remained specificity-forward. Conclusions: Using routinely available clinical and sociodemographic variables, LR and BN matched or exceeded XGBoost in externally validated performance and produced more reliable probability estimates. Model choice should align with intended use: BN (or LR) is preferable for sensitivity-forward screening, whereas XGBoost may be reserved for high-threshold confirmatory decisions only after recalibration. Across methods, psychiatric history, nephropathy, arthritis, gastropathy, household registration status, and BMI emerged as stable markers of vulnerability to depressive symptoms in pulmonary dysfunction.